Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

Insilico Out-Licenses Global Rights for USP1 Inhibitor to Exelixis for $80 Million Upfront

publication date: Sep 13, 2023

Insilico Medicine, a Hong Kong-New York AI drug discovery company, out-licensed global rights to a small molecule inhibitor of USP1 for BRCA-mutated tumors to Exelixis of Alameda, California. Exelixis will pay $80 million upfront plus unspecified milestones and royalties. USP1 repairs DNA damage by removing ubiquitin from multiple substrates. Exelixis will also have rights to other Insilico-discovered USP1 candidates. Founded in 2018, Insilico has partnered with US and China biopharmas to discover candidates for specific targets, including a six-drug deal worth up to $1.2 billion with Sanofi. More details....

Stock Symbol: (NSDQ: EXEL)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming Events

ChinaBio® Partnering Forum
September 10–11, 2024 | Shanghai, China
Register here


BIO-Europe®
November 4–6, 2024 | Stockholm, Sweden
Save €900 before September 13!
Register here


Biotech Showcase™
January 13–15, 2025 | San Francisco, CA
Save $600 before September 27!
Other Relevant Events

Antibody Engineering & Therapeutics Asia
October 21–23, 2024 | Kyoto, Japan
Save 30% with code CHINABIO30!
Register here